Eton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights

Dow Jones

03/03

By Elias Schisgall

Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns.

Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year.

The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products.

"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model," Eton Chief Executive Sean Brynjelsen said.

The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings.

Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 02, 2026 11:59 ET (16:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2616935424"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616935424\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616935424?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616935424","market":"hk","top_or_hot":-1,"title":"Eton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns. \n</p>\n<p>\n  Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year. \n</p>\n<p>\n  The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products. \n</p>\n<p>\n  \"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said. \n</p>\n<p>\n  The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings. \n</p>\n<p>\n  Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 11:59 ET (16:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEton Pharmaceuticals Rises on Acquisition of Hemangeol U.S. Commercialization Rights\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-03 00:59</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns. \n</p>\n<p>\n  Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year. \n</p>\n<p>\n  The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products. \n</p>\n<p>\n  \"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said. \n</p>\n<p>\n  The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings. \n</p>\n<p>\n  Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 11:59 ET (16:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ETON","symbol_name":"Eton Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616935424","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616935424","pubTimestamp":1772470740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns.Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year.The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products.\"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said.The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings.Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ETON":"Eton Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Eton Pharmaceuticals因收购Hemangeol美国商业化权而股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ETON":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Eton Pharmaceuticals rose after the company acquired U.S. commercialization rights to a treatment for proliferating infantile hemangioma, a form of non-cancerous tumor found in newborns. \n\n\n  Shares were up 8.2% at $18.39 in Monday morning trading. The stock has gained 22% in the past year. \n\n\n  The pharmaceutical company said Monday it has acquired the rights to Hemangeol, an oral solution developed by Pierre Fabre Medicament. With the acquisition, Eton said, it has reached a long-held goal of 10 commercial products. \n\n\n  \"As the only treatment for infantile hemangiomas that require systemic therapy, Hemangeol is a critical medication and a strong fit with Eton's orphan-focused commercial model,\" Eton Chief Executive Sean Brynjelsen said. \n\n\n  The acquisition will be financed with cash on hand and is expected to be accretive to 2026 earnings. \n\n\n  Eton will take over the U.S. commercialization of Hemangeol from Pierre Fabre on May 1. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 11:59 ET (16:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}